Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3
| T1CH34 Stock | 12.70 0.00 0.00% |
About 56% of Bio Techne's investor base is looking to short. The analysis of current outlook of investing in Bio Techne suggests that many traders are alarmed regarding Bio Techne's prospects. The current market sentiment, together with Bio Techne's historical and current headlines, can help investors time the market. In addition, many technical investors use Bio Techne stock news signals to limit their universe of possible portfolio assets.
Bio |
Filed transaction by Bio Techne Corp Director, Officer Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Bio Techne Fundamental Analysis
We analyze Bio Techne's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Bio Techne is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Bio Techne Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bio Techne stock to make a market-neutral strategy. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics with similar companies.
Peers
Bio Techne Related Equities
| D1FS34 | Discover Financial | 1.81 | ||||
| M1UF34 | Mitsubishi UFJ | 1.46 | ||||
| A1MP34 | Ameriprise Financial | 0.44 | ||||
| C1FG34 | Citizens Financial | 2.09 | ||||
| TRAD3 | TC Traders | 4.59 |
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |